デフォルト表紙
市場調査レポート
商品コード
1413390

関節リウマチ診断検査市場:検査タイプ別、エンドユーザー別-2024-2030年の世界予測

Rheumatoid Arthritis Diagnosis Tests Market by Test Type (Monitoring Rheumatoid Arthritis Treatment Efficiency Tests, Serology Test), End-User (Diagnostic Centers, Hospitals & Clinics) - Global Forecast 2024-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 196 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
関節リウマチ診断検査市場:検査タイプ別、エンドユーザー別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 196 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

関節リウマチ診断検査市場規模は2023年に29億8,000万米ドルと推計され、2024年には30億8,000万米ドルに達すると予測され、CAGR 4.69%で2030年には41億1,000万米ドルに達する見込みです。

関節リウマチ診断検査の世界市場

主な市場の統計
基準年[2023] 29億8,000万米ドル
予測年[2024] 30億8,000万米ドル
予測年 [2030] 41億1,000万米ドル
CAGR(%) 4.69%
関節リウマチ診断検査 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは関節リウマチ診断検査市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析は、関節リウマチ診断検査市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています:

1-市場の浸透度:主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度:有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化:新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報:市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション:将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています:

1-関節リウマチ診断検査市場の市場規模および予測は?

2-関節リウマチ診断検査市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か?

3-関節リウマチ診断検査市場における技術動向と規制の枠組みは?

4-関節リウマチ診断検査市場における主要ベンダーの市場シェアは?

5-関節リウマチ診断検査市場への参入に適した形態や戦略的手段は?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 世界中で関節リウマチの有病率が増加
      • 関節リウマチの治療と管理に対する支出の増加
      • 政府および世界的機関による関節リウマチに関する意識向上への取り組み
    • 抑制要因
      • 関節リウマチのヘルスケアサービスにアクセスすることに対する患者の抵抗感
    • 機会
      • MRI、超音波、HR-pQCT画像検査の改善と血清バイオマーカーパネルの開発
      • 関節リウマチの診断のための継続的な調査活動
    • 課題
      • 検査キットの特異性と感度が限られている
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 関節リウマチ診断検査市場テストタイプ別

  • 関節リウマチ治療効果のモニタリングテスト
    • クレアチニン検査
    • 筋肉酵素検査
    • サリチル酸レベルの数
  • 血清学検査
    • 抗環状シトルリン化ペプチド
    • 抗核抗体
    • 赤血球沈降速度
    • リウマチ因子(RF)
    • 尿酸

第7章 関節リウマチ診断検査市場:エンドユーザー別

  • 診断センター
  • 病院とクリニック

第8章 南北アメリカの関節リウマチ診断検査市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の関節リウマチ診断検査市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの関節リウマチ診断検査市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ主要企業別の分析

第12章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • Abbott Laboratories
    • Apollo Health and Lifestyle Limited
    • Arthritis Society Canada
    • Augurex Life Sciences Corporation
    • Beckman Coulter, Inc.
    • Bio-Rad Laboratories Inc.
    • Exagen Inc.
    • F. Hoffmann-La Roche AG
    • Genway Biotech, Inc.
    • Laboratory Corporation of America Holdings
    • QIAGEN GmbH
    • Remission Medical
    • Siemens Healthineers
    • Svar Life Sciences AB
    • Thermo Fisher Scientific, Inc.
  • 主要な製品ポートフォリオ

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET RESEARCH PROCESS
  • FIGURE 2. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET DYNAMICS
  • FIGURE 7. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
  • FIGURE 8. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 10. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 20. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 6. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 8. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY CREATININE TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MUSCLE ENZYME TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SALICYLATE LEVEL COUNT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 13. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTI-CYCLIC CITRULLINATED PEPTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ANTINUCLEAR ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY ERYTHROCYTE SEDIMENTATION RATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY RHEUMATOID FACTOR (RF), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY URIC ACID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 19. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY MONITORING RHEUMATOID ARTHRITIS TREATMENT EFFICIENCY TESTS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY SEROLOGY TEST, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 190. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. RHEUMATOID ARTHRITIS DIAGNOSIS TESTS MARKET LICENSE & PRICING
目次
Product Code: MRR-02026C4CB688

[196 Pages Report] The Rheumatoid Arthritis Diagnosis Tests Market size was estimated at USD 2.98 billion in 2023 and expected to reach USD 3.08 billion in 2024, at a CAGR 4.69% to reach USD 4.11 billion by 2030.

Global Rheumatoid Arthritis Diagnosis Tests Market

KEY MARKET STATISTICS
Base Year [2023] USD 2.98 billion
Estimated Year [2024] USD 3.08 billion
Forecast Year [2030] USD 4.11 billion
CAGR (%) 4.69%
Rheumatoid Arthritis Diagnosis Tests Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Rheumatoid Arthritis Diagnosis Tests Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Rheumatoid Arthritis Diagnosis Tests Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Rheumatoid Arthritis Diagnosis Tests Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Apollo Health and Lifestyle Limited, Arthritis Society Canada, Augurex Life Sciences Corporation, Beckman Coulter, Inc., Bio-Rad Laboratories Inc., Exagen Inc., F. Hoffmann-La Roche AG, Genway Biotech, Inc., Laboratory Corporation of America Holdings, QIAGEN GmbH, Remission Medical, Siemens Healthineers, Svar Life Sciences AB, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Rheumatoid Arthritis Diagnosis Tests Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Test Type
    • Monitoring Rheumatoid Arthritis Treatment Efficiency Tests
      • Creatinine Test
      • Muscle Enzyme Tests
      • Salicylate Level Count
    • Serology Test
      • Anti-Cyclic Citrullinated Peptide
      • Antinuclear Antibody
      • Erythrocyte Sedimentation Rate
      • Rheumatoid Factor (RF)
      • Uric Acid
  • End-User
    • Diagnostic Centers
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Rheumatoid Arthritis Diagnosis Tests Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Rheumatoid Arthritis Diagnosis Tests Market?

3. What are the technology trends and regulatory frameworks in the Rheumatoid Arthritis Diagnosis Tests Market?

4. What is the market share of the leading vendors in the Rheumatoid Arthritis Diagnosis Tests Market?

5. Which modes and strategic moves are suitable for entering the Rheumatoid Arthritis Diagnosis Tests Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Rheumatoid Arthritis Diagnosis Tests Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of rheumatoid arthritis worldwide
      • 5.1.1.2. Growing expenditure for the treatment and management of RA
      • 5.1.1.3. Awareness initiatives about RA by governments and global institutions
    • 5.1.2. Restraints
      • 5.1.2.1. Patients' reluctance to access healthcare services for RA
    • 5.1.3. Opportunities
      • 5.1.3.1. Improvements in MRI, ultrasound, and HR-pQCT imaging tests and development of serum biomarker panel
      • 5.1.3.2. Ongoing research activities for the diagnosis of RA
    • 5.1.4. Challenges
      • 5.1.4.1. Limited specificity and sensitivity of test kits
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Rheumatoid Arthritis Diagnosis Tests Market, by Test Type

  • 6.1. Introduction
  • 6.2. Monitoring Rheumatoid Arthritis Treatment Efficiency Tests
    • 6.3.1. Creatinine Test
    • 6.3.2. Muscle Enzyme Tests
    • 6.3.3. Salicylate Level Count
  • 6.3. Serology Test
    • 6.4.1. Anti-Cyclic Citrullinated Peptide
    • 6.4.2. Antinuclear Antibody
    • 6.4.3. Erythrocyte Sedimentation Rate
    • 6.4.4. Rheumatoid Factor (RF)
    • 6.4.5. Uric Acid

7. Rheumatoid Arthritis Diagnosis Tests Market, by End-User

  • 7.1. Introduction
  • 7.2. Diagnostic Centers
  • 7.3. Hospitals & Clinics

8. Americas Rheumatoid Arthritis Diagnosis Tests Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Rheumatoid Arthritis Diagnosis Tests Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Rheumatoid Arthritis Diagnosis Tests Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

  • 12.1. Key Company Profiles
    • 12.1.1. Abbott Laboratories
    • 12.1.2. Apollo Health and Lifestyle Limited
    • 12.1.3. Arthritis Society Canada
    • 12.1.4. Augurex Life Sciences Corporation
    • 12.1.5. Beckman Coulter, Inc.
    • 12.1.6. Bio-Rad Laboratories Inc.
    • 12.1.7. Exagen Inc.
    • 12.1.8. F. Hoffmann-La Roche AG
    • 12.1.9. Genway Biotech, Inc.
    • 12.1.10. Laboratory Corporation of America Holdings
    • 12.1.11. QIAGEN GmbH
    • 12.1.12. Remission Medical
    • 12.1.13. Siemens Healthineers
    • 12.1.14. Svar Life Sciences AB
    • 12.1.15. Thermo Fisher Scientific, Inc.
  • 12.2. Key Product Portfolio

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing